Literature DB >> 30314805

Neurofibromatosis type 2: Hearing preservation and rehabilitation.

H Jia1, M M El El Sayed2, M Smail3, I Mosnier4, H Wu5, O Sterkers6, M Kalamarides7, D Bernardeschi3.   

Abstract

The main manifestation of neurofibromatosis type 2 (NF2) is the development of bilateral vestibular schwannomas (VS). Consequently, one of the most severe functional sequelae is bilateral sensorineural hearing loss, caused by spontaneous tumor progression and/or treatment-related damage (surgery or radiosurgery). Preserving or restoring hearing is still challenging in NF2 no matter the strategy applied to each individual based on the natural history of VS. In this review, the different strategies for hearing preservation or rehabilitation are discussed and illustrated by several cases. A decisional algorithm for NF2 patients with VS is proposed that takes into consideration the tumor size and hearing level.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Auditory brainstem implant; Cochlear implant; Hearing loss; Vestibular schwannoma

Mesh:

Year:  2018        PMID: 30314805     DOI: 10.1016/j.neuchi.2018.09.003

Source DB:  PubMed          Journal:  Neurochirurgie        ISSN: 0028-3770            Impact factor:   1.553


  4 in total

Review 1.  The emerging role of hearing loss rehabilitation in patients with vestibular schwannoma treated with Gamma Knife radiosurgery: literature review.

Authors:  Carlotta Morselli; N Boari; M Artico; M Bailo; L O Piccioni; I Giallini; M de Vincentiis; P Mortini; P Mancini
Journal:  Neurosurg Rev       Date:  2020-02-06       Impact factor: 3.042

2.  Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis.

Authors:  Umberto Tosi; Omri Maayan; Anjile An; Miguel E Tusa Lavieri; Sergio W Guadix; Antonio P DeRosa; Paul J Christos; Susan Pannullo; Philip E Stieg; Andrew Brandmaier; Jonathan P S Knisely; Rohan Ramakrishna
Journal:  J Neurooncol       Date:  2022-01-18       Impact factor: 4.130

3.  Patient Report of Hearing in Neurofibromatosis Type 2: Recommendations for Clinical Trials.

Authors:  Heather L Thompson; Ann Blanton; Barbara Franklin; Vanessa L Merker; Kevin H Franck; D Bradley Welling
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

4.  p53 and merlin tumor suppressors: Two of a kind.

Authors:  Rebecca Voltan
Journal:  EBioMedicine       Date:  2018-10-29       Impact factor: 8.143

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.